Merils Myval THV series put India at forefront in heartvalve technology, recognised at EuroPcr'24 and accepted in The Lancet
May 16, 2024
Vapi (Gujarat) [India], May 16: Exciting news from Meril Life Sciences! The LANDMARK trial's 30 days primary outcomes were presented on 15th May at EuroPCR 2024, Paris, France. LANDMARK was recognized by EuroPCR as one of the top three late breaking trials poised to transform revolutionise current practices in the field of Interventional Cardiology.
Read More...